Search results
Results from the WOW.Com Content Network
The effects of psychedelics on neuroplasticity appear to be dependent on serotonin 5-HT 2A receptor activation, as they are abolished in 5-HT 2A receptor knockout mice. [7] Non-hallucinogenic serotonin 5-HT 2A receptor agonists, like tabernanthalog and lisuride, have also been found to increase neuroplasticity, and to a magnitude comparable to ...
Drugs of abuse increase the VTA's ability to project dopamine to the rest of the reward circuit. [6] These structural changes only last 7–10 days, [ 7 ] however, indicating that the VTA cannot be the only part of the brain that is affected by drug use, and changed during the development of addiction.
The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was by Corneliu E. Giurgea in 1972. [ 5 ] [ 6 ] [ 7 ] When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the concept ...
Innovative treatments are still needed for areas where relevant therapies are unavailable. [4] Consistent aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of certain drug addictions and is an effective adjunct treatment for drug addiction, and for psychostimulant addiction in particular.
[14] [17] The United States Food and Drug Administration has granted "breakthrough therapy" status, which expedites the potential approval of promising drug therapies, [note 2] to psychedelic therapies using psilocybin (for treatment-resistant depression and major depressive disorder) [8] and MDMA (for post-traumatic stress disorder).
Psychedelic microdosing involves consuming sub-threshold doses of serotonergic psychedelic drugs like LSD and psilocybin to potentially enhance creativity, energy, emotional balance, problem-solving abilities, and to address anxiety, depression, [1] and addiction.
Stigmatization of drug use, the War on Drugs and criminalization, and the social determinants of health should all be considered when discussing access to drug treatment and potential barriers. Broad categories of barriers to drug treatment are: absences of problem, negative social support, fear of treatment, privacy concerns, time conflict ...
Approved for treating narcolepsy, obstructive sleep apnea, and shift work sleep disorder, modafinil is a wakefulness-promoting drug used to decrease fatigue, increase vigilance, and reduce daytime sleepiness. [1] Modafinil improves alertness, attention, long-term memory, and daily performance in people with sleep disorders. [1] [18]